What Blends Are There? GLOW70, BT20 Composition and Mechanisms
Blends are multi-ingredient formulations with fixed input ratios. Each entry covers spec code, composition, mechanism, related items, and links back to single-ingredient pages and scenario guides.
The Scientific Logic of Blends
Section titled “The Scientific Logic of Blends”A single ingredient addresses a single pathway; tissue repair, metabolism, and anti-aging usually involve multiple pathways in parallel. The value of fixed ratios:
- Multiple pathways in parallel: processes such as blood supply, migration, and anti-inflammatory action occur simultaneously during repair.
- Traceable ratios: fixed input ratios make experimental controls and literature comparisons easier.
- Easy to discuss: fixed ratios make mechanism comparisons and experimental designs reproducible.
| Scenario pain point | Blend | Mechanism highlights |
|---|---|---|
| Redness after energy-based procedures, weak barrier, wants collagen | GLOW70 | Repair + blood vessels + migration in one line |
| Tendons and ligaments that keep failing to heal | BT20 / WOLVERINE22 | Repair + (anti-inflammatory) |
| Poor sleep, poor body composition, anti-aging | CI10 / CI20 | GH pulses, no water retention |
| Large belly, visceral fat | TSM10IPA5 | Lipolysis + lean-mass preservation |
| Weight-loss plateau, appetite won’t come down | SM5CAG5 / TR30CAG5 | Dual-pathway appetite suppression |
By Physiological Problem
Section titled “By Physiological Problem”GLOW70 is the flagship object for aesthetic procedures: GHK-Cu drives collagen and basement membrane support, BPC-157 provides microvascular support, and TB-500 handles cell migration.
Further reading: GLOW70, GHK-Cu
- Scenario: Post-Laser Recovery
From light maintenance to severe inflammation, choose by load:
| Object | Positioning |
|---|---|
| BT10 / B5T5 | Chronic overuse strain, mild sprains |
| BT20 / B10T10 | Mainstay for tendons, ligaments, and meniscus |
| WOLVERINE22 | Severe injury + anti-inflammatory + adhesion prevention |
| Object | Positioning |
|---|---|
| CI10 / CI20 | GH-pulse anti-aging, sleep recovery |
| TSM10IPA5 | Visceral fat, central obesity |
| KLOTHO60 | Telomere/circadian deep anti-aging |
| NM530 | Mitochondrial energy, chronic fatigue |
| Object | Backbone | Positioning |
|---|---|---|
| SM5CAG5 | Semaglutide + Cagrilintide | Plateau, dual-pathway appetite suppression |
| TR30CAG5 | Tirzepatide + Cagrilintide | High body weight, glucose control and weight loss |
| RT15CAG5 | Retatrutide + Cagrilintide | Triple target, research frontier for severe obesity |
For mechanism comparison, see GLP-1 Drugs.
GLOW70
Section titled “GLOW70”A fixed-ratio blend of GHK-Cu, BPC-157, and TB-500, covering three repair-related pathways: collagen/basement membrane, microvasculature, and cell migration.
| Attribute | Value |
|---|---|
| Spec code | GLOW70 |
| Type | Blend, Aesthetic repair |
| Composition | GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg |
| Mechanism | GHK-Cu supports collagen and the basement membrane; BPC promotes microvascular angiogenesis; TB-500 drives cell migration |
| Scenario | Post-procedure repair, collagen plumping, barrier resilience |
Mechanistically overlaps with GHK-Cu, BPC-157, and TB-500; read side by side. Related to the problem scenarios in Post-Laser Recovery and Collagen Aging.
B10T10 / BT20
Section titled “B10T10 / BT20”An equal-ratio combination of BPC-157 and TB-500, often used to discuss blood supply and migration in tendon and ligament repair.
| Attribute | Value |
|---|---|
| Spec code | B10T10 / BT20 |
| Type | Blend, Sports injuries |
| Composition | BPC-157 10mg + TB-500 10mg |
| Mechanism | BPC builds microvasculature; TB-500 regulates actin remodeling |
| Scenario | Tendon and ligament tears, meniscus, Achilles tendon injuries |
Mechanistically overlaps with BPC-157, TB-500, BT10, and WOLVERINE22; read side by side. Related to the problem scenarios in Tendon Recovery and Ligament and Meniscus.
B5T5 / BT10
Section titled “B5T5 / BT10”A lower-dose combination on the same pathways as BT20, convenient for dose comparison.
| Attribute | Value |
|---|---|
| Spec code | B5T5 / BT10 |
| Type | Blend, Low-dose maintenance |
| Composition | BPC-157 5mg + TB-500 5mg |
| Mechanism | Same pathways as BT20, low-dose synergy |
| Scenario | Chronic joint overuse strain, mild muscle strains |
Mechanistically overlaps with BT20 and BPC-157; read side by side.
CND5IPA5 / CI10
Section titled “CND5IPA5 / CI10”A GHRH/GHS dual-pathway combination of CJC-1295 (No DAC) and Ipamorelin, close to pulsatile secretion.
| Attribute | Value |
|---|---|
| Spec code | CND5IPA5 / CI10 |
| Type | Blend, GH anti-aging |
| Composition | CJC-1295 No DAC 5mg + Ipamorelin 5mg |
| Mechanism | GHRH receptor + GHS-R1a dual target, mimicking physiological pulses |
| Scenario | Deep-sleep recovery, body recomposition, firming without water retention |
Mechanistically overlaps with CJC-1295 No DAC, Ipamorelin, and CI20; read side by side. Related to the problem scenarios in Deep Sleep and Growth Hormone and Anti-Aging.
CND10IPA10 / CI20
Section titled “CND10IPA10 / CI20”The same combination as CI10 in a larger spec ratio, convenient for long-cycle comparison.
| Attribute | Value |
|---|---|
| Spec code | CND10IPA10 / CI20 |
| Type | Blend, Large-spec anti-aging |
| Composition | CJC-1295 No DAC 10mg + Ipamorelin 10mg |
| Mechanism | Dual target maintained at a larger dose |
| Scenario | High-frequency conditioning, monthly protocols |
Mechanistically overlaps with CI10 and TSM10IPA5; read side by side.
TSM10IPA5
Section titled “TSM10IPA5”A Tesamorelin and Ipamorelin combination, used in visceral fat and metabolism discussions.
| Attribute | Value |
|---|---|
| Spec code | TSM10IPA5 |
| Type | Blend, Abdominal fat |
| Composition | Tesamorelin 10mg + Ipamorelin 5mg |
| Mechanism | Tesamorelin favors visceral fat breakdown; Ipamorelin preserves lean mass |
| Scenario | Central obesity, stubborn belly fat, fatty-liver-related metabolism |
Mechanistically overlaps with Tesamorelin and Ipamorelin; read side by side. Related to the problem scenarios in Visceral Fat.
SM5CAG5
Section titled “SM5CAG5”A Semaglutide and Cagrilintide combination, covering GLP-1 and amylin dual pathways.
| Attribute | Value |
|---|---|
| Spec code | SM5CAG5 |
| Type | Blend, Weight management |
| Composition | Semaglutide 5mg + Cagrilintide 5mg |
| Mechanism | GLP-1 delays gastric emptying + amylin pathway suppresses appetite |
| Scenario | Weight-loss plateau, dual-pathway appetite suppression |
Mechanistically overlaps with Semaglutide, Cagrilintide, TR30CAG5, and RT15CAG5; read side by side. Related to the problem scenarios in Weight-Loss Plateau.
TR30CAG5
Section titled “TR30CAG5”A Tirzepatide and Cagrilintide combination: dual incretins plus amylin.
| Attribute | Value |
|---|---|
| Spec code | TR30CAG5 |
| Type | Blend, High body weight |
| Composition | Tirzepatide 30mg + Cagrilintide 5mg |
| Mechanism | GIP/GLP-1 + amylin |
| Scenario | High body-weight management, glucose control and weight loss in parallel |
Mechanistically overlaps with Tirzepatide and Cagrilintide; read side by side.
RT15CAG5
Section titled “RT15CAG5”A Retatrutide and Cagrilintide combination: triple receptors plus amylin.
| Attribute | Value |
|---|---|
| Spec code | RT15CAG5 |
| Type | Blend, Triple-target metabolism |
| Composition | Retatrutide 15mg + Cagrilintide 5mg |
| Mechanism | GLP-1/GIP/GCGR + amylin |
| Scenario | Severe obesity, hepatic fat research directions |
Mechanistically overlaps with Retatrutide and Cagrilintide; read side by side.
WOLVERINE22 / BTK22
Section titled “WOLVERINE22 / BTK22”A BPC-157, TB-500, and KPV combination: repair pathways stacked with anti-inflammatory pathways.
| Attribute | Value |
|---|---|
| Spec code | WOLVERINE22 / BTK22 |
| Type | Blend, Severe injury anti-inflammatory |
| Composition | BPC-157 10mg + TB-500 10mg + KPV 2mg |
| Mechanism | Vascular regeneration + cell migration + KPV inhibits NF-κB |
| Scenario | Severe sports injuries, synovitis, post-surgical adhesion prevention |
Mechanistically overlaps with BT20, KPV, and BPC-157; read side by side. Related to the problem scenarios in Scar Adhesion and Joint Care.
KLOTHO60
Section titled “KLOTHO60”An Epithalon and GHK-Cu combination: telomere/circadian support plus GHK-Cu repair.
| Attribute | Value |
|---|---|
| Spec code | KLOTHO60 |
| Type | Blend, Deep anti-aging |
| Composition | Epithalon 50mg + GHK-Cu 10mg |
| Mechanism | Telomere/circadian-related + GHK-Cu antioxidant gene regulation |
| Scenario | Cellular-level anti-aging, sleep-circadian conditioning |
Mechanistically overlaps with Epithalon and GHK-Cu; read side by side. Related to the problem scenarios in Cellular Aging and Deep Sleep.
NM530 / NAD-MOTS
Section titled “NM530 / NAD-MOTS”An NAD+ and MOTS-c combination: energy coenzyme plus AMPK-related action.
| Attribute | Value |
|---|---|
| Spec code | NM530 / NAD-MOTS |
| Type | Blend, Mitochondrial energy |
| Composition | NAD+ 500mg + MOTS-c 30mg |
| Mechanism | NAD+ coenzyme substrate + AMPK glucose metabolism |
| Scenario | Chronic fatigue, insulin resistance, metabolic renewal |
Mechanistically overlaps with MOTS-c and SS-31; read side by side. Related to the problem scenarios in Chronic Fatigue and Insulin Resistance.
SX10SL10 / BRAIN20
Section titled “SX10SL10 / BRAIN20”A Semax and Selank combination along two lines: cognition and mood regulation.
| Attribute | Value |
|---|---|
| Spec code | SX10SL10 / BRAIN20 |
| Type | Blend, Cognition and mood |
| Composition | Semax 10mg + Selank 10mg |
| Mechanism | BDNF/NGF cognitive activation + GABA mood stabilization |
| Scenario | High-pressure focus, mental efficiency, stress resilience |
Mechanistically overlaps with Semax and Selank; read side by side. Related to the problem scenarios in Brain Fog and Focus and Stress and Anxiety.
KP10PT10
Section titled “KP10PT10”A Kisspeptin-10 and PT-141 combination: GnRH axis plus central melanocortin.
| Attribute | Value |
|---|---|
| Spec code | KP10PT10 |
| Type | Blend, Endocrine for both sexes |
| Composition | Kisspeptin-10 10mg + PT-141 10mg |
| Mechanism | GPR54–GnRH axis + central melanocortin |
| Scenario | Arousal response, endocrine-axis synergy |
Mechanistically overlaps with PT-141 and Kisspeptin-10; read side by side.
Key References
Section titled “Key References”For single-ingredient references, see BPC-157, GHK-Cu, and GLP-1; combination mechanisms are multi-pathway in parallel, not additive efficacy claims.
Blend ingredient references: BPC-157 PMID: 40005999; GLP-1 PMID: 33567185.
How to Read Blends
Section titled “How to Read Blends”The value of a blend is a framework for discussing parallel mechanisms, not “more is better”. Read a blend by its naming and ratio logic first.
Additivity, Synergy, and Antagonism
Section titled “Additivity, Synergy, and Antagonism”Additivity is the sum of independent contributions; synergy means mutual amplification; antagonism can mean interference with stability or receptor sensitivity. The “mechanism” rows of each formula on this page state parallel-pathway hypotheses, not clinical efficacy promises (for blend-versus-single comparisons see Recovery Peptides and GLP-1 Drugs).
How to Read Ratio Numbers
Section titled “How to Read Ratio Numbers”The numbers in a name are milligram ratios of each component, not a potency ranking: in a 10+10 combination the peptides still differ in molecular weight, purity, and actual delivered amount. Specification and testing conventions for singles are in How to Read a COA, and spec-code naming in Peptide Guide.
This page does not constitute medical advice; blend ratios facilitate mechanism discussion and are not individualized prescriptions — any use should follow a physician’s guidance.
Related Reading
Section titled “Related Reading”Safety Boundaries and Limitations
Section titled “Safety Boundaries and Limitations”Blend ratios make mechanism discussion easy; they are not optimal clinical formulas. This page contains no dosing protocols.
Practical workflow and quality control: before using or comparing an ingredient, see reconstitution, storage, COA, and administration routes; operating standards in Peptide Basics.